Table 1.
Cohort demographics and clinical characteristics.
| Characteristic | Entire cohort n = 113 | Time period 1: n = 60 | Time period 2: N = 53 | Test statistic |
|---|---|---|---|---|
| Mean (SD) | Mean (SD) | Mean (SD) | t (p) | |
| Age | 51.1 (13.1) | 53.19 (11.30) | 48.85 (14.70) | 1.72 (0.09) |
| Initial tumor size (cm) | 3.35 (2.2) | 3.43 (2.2) | 2.49 (1.48) | 2.51 (0.01)∗ |
| BMI | 27.8 (7.4) | 28.81 (8.13) | 26.7 (6.43) | 1.50 (0.14) |
|
| ||||
| N (%) | N (%) | N (%) | χ 2 (p) | |
|
| ||||
| Clinical LAD | 65 (57.5) | 37 (61.7) | 28 (52.8) | 0.88 (0.35) |
| Hormonal receptor positive only | 33 (29.2) | 22 (36.7) | 11 (20.7) | 4.18 (0.04)∗ |
| HER2+ | 43 (38.1) | 17 (28.3) | 26 (49.1) | 4.92 (0.03)∗ |
| TNBC | 37 (32.7) | 21 (35.0) | 16 (30.2) | 0.28 (0.60) |
| pCR overall | 30 (26.5) | 8 (13.3) | 22 (41.5) | 11.36 (0.001)∗∗ |
BMI: body mass index; HER2: human epidermal growth factor receptor 2; LAD: lymphadenopathy; NACT: neoadjuvant chemotherapy; pCR: pathological complete response; time period 1: before 12/2013; time period 2: after 12/2013; TNBC: triple negative breast cancer.
Notes. ∗∗ p < 0.01 and ∗ p < 0.05.